Researchers have announced that two new obesity medications, Foundayo and Zepbound, are now covered by CVS Caremark, making them accessible to millions of Americans. Foundayo is a once-daily oral medication that can be taken without food or water restrictions, while Zepbound is an injectable treatment that has become the most prescribed weight management drug. Both medications aim to help adults with obesity or overweight who have weight-related health issues lose weight and maintain that loss.

This coverage expansion is significant for people looking to manage their weight effectively. For instance, in clinical trials, participants using Foundayo lost an average of 27.3 pounds over 72 weeks, while those using Zepbound lost an average of 34 to 48 pounds, depending on the dose. These results highlight the potential for these medications to support weight loss efforts alongside a healthy diet and increased physical activity, which are crucial for long-term health and well-being.

The evidence supporting these medications comes from large clinical trials involving thousands of participants. Foundayo’s effectiveness was demonstrated in the ATTAIN trials, which included over 4,500 individuals, while Zepbound’s results were backed by the SURMOUNT-1 trial, showing sustained weight loss over 72 weeks. However, while the results are promising, it is important to recognize that these medications should be used in conjunction with lifestyle changes, and they may come with potential side effects, including risks of thyroid tumors.

If you’re considering these medications, it’s essential to talk to your healthcare provider to determine if they are appropriate for you. They can help you understand the benefits and risks, as well as how to incorporate these treatments into a broader weight management strategy.

Source: investor.lilly.com